SPIRE II

SPIRE (Studies of PCSK9 Inhibition and the Reduction of vascular Events) was an extensive research program to study bococizumab, an investigational PCSK9i. 

Therapeutic areas

Total patients

11000

Total sites

451

Status

Finished

The cardiovascular outcome study investigated the ability of bococizumab to reduce the risk of cardiovascular events in a broad range of high-risk primary and secondary prevention patients, including those with diabetes, chronic kidney disease, peripheral vascular disease or familial hypercholesterolemia. It also included those with previous cardiovascular events such as heart attack, stroke, or cardiovascular revascularization procedures.

The SPIRE cardiovascular outcome program for bococizumab is the only PCSK9i research program explicitly assessing cardiovascular outcomes in high-risk primary and secondary prevention patients with an LDL-C ≥100mg/dL, despite the use of highly-effective statins or with documented partial or complete statin intolerance.

Publications

No publications yet

show details